InSphero announced it has acquired PhenoVista Biosciences, a cell-based assay services provider specializing in high-content imaging and phenotypic assay technologies. The deal is expected to expand InSphero’s assay and service portfolio across oncology, fibrosis, and safety assessment, while also strengthening its neuroscience and neurotoxicity testing capabilities. InSphero said the acquisition supports growth of its U.S. footprint and complements its existing organ-on-a-chip and 3D cell assay platform activities. The companies did not disclose financial terms. The acquisition reflects continued CDMO-adjacent consolidation in functional testing and imaging-driven drug discovery as sponsors increasingly seek integrated, phenotypic readouts for faster decision-making.